China is swiftly emerging as a global leader in drug innovation, fueled by soaring investments, state-of-the-art technology, and a dynamic biotech sector, reports China Daily. The nation is determined to accelerate breakthrough treatments and transform the future of healthcare development
Japan’s health panel has just approved the first-ever over-the-counter sale of an erectile dysfunction drug, marking a groundbreaking step forward in making treatment more accessible for men nationwide, officials announced Tuesday
Jim Cramer shines a spotlight on Novo Nordisk A/S (NVO) as “Canada’s backdoor” in a recent Insider Monkey report, highlighting the pharma giant’s daring strategies and thrilling growth prospects throughout North America
Exciting news from the world of biopharmaceuticals! Abiogen and mAbxience have joined forces in a groundbreaking collaboration in Italy, set to revolutionize the landscape of biopharmaceutical development. By harnessing their collective expertise, this dynamic partnership aims to propel innovative therapies forward and significantly enhance patient outcomes across the region.
In a groundbreaking move, Australia has officially greenlit the first-ever drug for early-stage Alzheimer’s disease, heralding a remarkable leap forward in the fight against this challenging condition. This exciting breakthrough brings renewed hope to countless patients and their families grappling with the impact of Alzheimer’s.
An Indian drugmaker, once under the microscope of ProPublica, has announced a recall of two dozen medications that were sent to patients across the U.S. This alarming development has sparked fresh concerns about the safety and quality of drugs, especially in light of previous investigations that uncovered troubling issues within the company.
Eli Lilly’s recent launch of Mounjaro in India has sparked a surge in inquiries about weight-loss solutions. The new drug, aimed at managing obesity, has captured significant attention, reflecting a growing demand for effective weight management options in the country.
Canada has added a commonly prescribed blood pressure medication to its drug shortages website, raising concerns among healthcare professionals about potential impacts on patient care. Authorities urge patients to consult with their physicians for alternatives.
In a recent announcement, former President Donald Trump renewed threats of tariffs on Indian pharmaceutical imports, marking a sudden shift that has negatively impacted Indian pharma stocks. Investors reacted swiftly, reversing the brief respite enjoyed by the sector.
Australia’s trade tensions with the Trump administration escalated over affordable medicines. The U.S. criticized Australia’s pharmaceutical pricing policies, arguing they undermined fair trade, while Australia defended its system aimed at ensuring low-cost access to essential drugs.
Eli Lilly is set to introduce its weight-loss drug in emerging markets this year, aiming to address rising obesity rates. The launch follows successful outcomes in developed regions, positioning Lilly to expand its global footprint in the competitive weight management sector.
A recent investigation by BBC reveals that an Indian pharmaceutical company is significantly contributing to West Africa’s escalating opioid crisis. The report highlights alarming practices, including the production and distribution of potent opioids, raising concerns about public health and regulatory oversight in the region.
